Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vonicog alfa + octocog alfa
- Development stage
- Phase 1
- Lead developer
- Takeda
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
This is a **combination therapy** of **vonicog alfa** (recombinant von Willebrand factor, rVWF) and **octocog alfa** (recombinant factor VIII, rFVIII), used for rapid correction of hemostasis in adult patients with von Willebrand disease (VWD) when desmopressin is ineffective or inappropriate and rapid Factor VIII coagulant activity (FVIII:C) correction is needed. Vonicog alfa restores platelet adhesion at vascular injury sites and stabilizes endogenous factor VIII; octocog alfa directly increases FVIII levels. Their combined administration normalizes both VWF and FVIII:C, facilitating clot formation in acute bleeding or surgery[5][7].
- Brand names
- VEYVONDI + ADVATE
- Other names
- recombinant von Willebrand factor + recombinant factor VIIIrVWF + rFVIII
02
Targets
F8 (Coagulation Factor VIIIa)Collagen / subendothelial matrixCoagulation Factor IXaBB-031 (Von Willebrand factor)
Beyond the preview
Go deeper on vonicog alfa + octocog alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vonicog alfa + octocog alfa.